ProAgio and gemcitabine for triple-negative breast cancer that has spread
Part of Cancer, Skin clinical trials.
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your breast cancer must be triple-negative (ER, PR, and HER2 negative) and has spread to other organs.
- You must have already tried at least two different treatments for advanced cancer.
- You must be willing to provide a tumor sample and have a research biopsy before and during treatment.
- You need to be in generally good health with adequate blood cell counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two chemotherapy drugs (gemcitabine and paclitaxel) to see which works better for advanced breast cancer that has spread, specifically in Caribbean women of African ancestry. The goal is to find the most effective treatment option for this type of cancer in your community.
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
This trial tests a combination of a PD-L1 antibody (a type of immunotherapy) with a low-dose, continuous chemotherapy regimen called VEX for advanced triple-negative breast cancer that has spread to other parts of the body. It may be an option if you have had only one prior chemotherapy for metastatic disease and have already been treated with certain common chemo drugs.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests a new drug called ProAgio combined with standard chemotherapy for people with stage IV pancreatic cancer. It aims to see if the combination is safe and effective.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.